Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Herpetic esophagitis following bendamustine-containing regimen

Authors Yamane H, Monobe Y, Tanikawa T, Ochi N, Honda Y, Kawamoto H, Takigawa N

Received 13 October 2015

Accepted for publication 31 January 2016

Published 2 June 2016 Volume 2016:12 Pages 883—886

DOI https://doi.org/10.2147/TCRM.S98217

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Chang Liu

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Hiromichi Yamane,1 Yasumasa Monobe,2 Tomohiro Tanikawa,3 Nobuaki Ochi,1 Yoshihiro Honda,1 Hirofumi Kawamoto,3 Nagio Takigawa1

1Department of General Internal Medicine 4, 2Department of Pathology, 3Department of General Internal Medicine 2, Kawasaki Medical School, Kita-ku, Okayama, Japan

Abstract: A 76-year-old Japanese woman presented to our hospital with anorexia. Two years before, she was diagnosed with non-Hodgkin’s lymphoma and had received ten cycles of systemic chemotherapy. After salvage chemotherapy with bendamustine and rituximab (B–R), bone marrow suppression had lasted >3 months. Esophagogastroscopy revealed polynesic white protrusions in the mid-esophagus. These lesions were diagnosed as herpetic esophagitis. To the best of our knowledge, there is no other report in which herpetic esophagitis has been documented as an adverse event of B–R regimen. Because the complication could cause symptomatic gastrointestinal discomfort, physicians should be aware of this disease.

Keywords: bendamustine, herpetic esophagitis, immunodeficiency, non-Hodgkin’s lymphoma, rituximab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation

Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, Hisamoto A, Kiura K, Takigawa N

OncoTargets and Therapy 2013, 6:155-160

Published Date: 6 March 2013